Drug Pipeline

NT-I7 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
3
Recruiting
2
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-11 NCT07200089
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA…		 Recruitment opened
2026-06-11 NCT07200089
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA…		 date change Completion pushed: 2028-11-30 -> 2028-12-31
Active Studies by Phase
Phase 2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT05465954 Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma High Grade Astrocytic Tumor Recruiting
Phase 1
NCT07052305 NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or… Large B-cell Lymphoma Recruiting
NCT07200089 Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA… Multiple Myeloma Recruiting
Sponsors Running NT-I7 Trials
Washington University School of Medicine (2) Mayo Clinic (1)
Disease Areas
Glioblastoma (1) Sarcoma (1) Multiple Myeloma (1)
Get alerts when NT-I7 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free